Evolutionary processes shape bacterial populations in the human gut
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 19:15 ET (22-Jun-2026 23:15 GMT/UTC)
A new trial will test whether a tool that harnesses Apple Watch health data and artificial intelligence can help protect children undergoing cancer treatment from infections.
How does the innate immune system distinguish pathogens from self-components while avoiding excessive immune response and inflammation? Toll-like receptors (TLRs) have provided the answer to this central question over four decades of research. This review synthesizes the multilayered and interactive regulatory mechanisms—from post-translational modifications to phase separation—that ensure balanced TLR signaling, and explores the translational promise of targeting these pathways in infectious diseases, autoimmune diseases, cancer, and inflammatory aging.
A multicenter study found that the advanced lung cancer inflammation index (ALI) predicts outcomes in acute ischemic stroke patients receiving thrombolysis. Lower ALI levels were strongly linked to poorer functional recovery, with a non-linear J-shaped relationship and a threshold effect. Derived from routine clinical measures, ALI offers a simple, accessible biomarker for early risk stratification.
How cells precisely control the timing of mRNA activation during differentiation is a longstanding question in molecular biology. In this study, researchers uncovered the MX-H pathway and MXL vesicles as the machinery responsible for removing inhibitory RNA-binding proteins and unleashing stored mRNAs at the right moment for sperm maturation. Importantly, the team found that this germ cell-specific system is hijacked by gastric cancer to promote tumor growth. These findings not only illuminate a fundamental regulatory mechanism in development but also identify a promising new target for selective cancer therapy.
New research shows that the same genes are active in pancreatic cancer, obesity and diabetes, helping to explain why people with metabolic disease often face poorer cancer outcomes and pointing to future ways to predict recurrence and develop more targeted treatments.